TOP > 外国特許検索 > AGENT FOR PREVENTING, AMELIORATING OR TREATING ACANTHOTIC DISEASE AND/OR ACANTHOTIC SYMPTOM

AGENT FOR PREVENTING, AMELIORATING OR TREATING ACANTHOTIC DISEASE AND/OR ACANTHOTIC SYMPTOM NEW

外国特許コード F190009759
整理番号 (S2017-0737-N0)
掲載日 2019年5月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP019345
国際公開番号 WO 2018212341
国際出願日 平成30年5月18日(2018.5.18)
国際公開日 平成30年11月22日(2018.11.22)
優先権データ
  • 特願2017-100149 (2017.5.19) JP
発明の名称 (英語) AGENT FOR PREVENTING, AMELIORATING OR TREATING ACANTHOTIC DISEASE AND/OR ACANTHOTIC SYMPTOM NEW
発明の概要(英語) The present invention addresses the problem of providing an active ingredient having an effect of preventing, ameliorating or treating an acanthotic disease and/or an acanthotic symptom. This problem is solved by an agent for preventing, ameliorating or treating an acanthotic disease and/or an acanthotic symptom, said agent comprising at least one member selected from the group consisting of phospholipase D and an expression cassette thereof.
従来技術、競合技術の概要(英語) BACKGROUND ART
Lipid homeostasis of the skin is considered very important in a biological component. For example, the epidermis of the skin surface in contact with the external world (keratinocytes) ceramide of keratinocytes (a kind of sphingolipids) of the formed layer, such as a pathogen or evaporation of water from the body of the body from entering with a hotspot. Keratinocyte differentiation and proliferation of the cycle is broken, the disturbance of the barrier of the skin, including diseases such as psoriasis skin thickening, such as the stratum corneum ichthyosis severe deficiency disease, atopic dermatitis and further, such as allergic diseases leads to contact dermatitis.
Sphingolipids in addition, the living body is present in the lipid having a glycerol backbone. Phospholipid glycerophospholipides 1 of one of the main components and the cell membrane, its metabolic abnormality is involved in various disease. Glycerophospholipids is, in a manner that the coupling of the glycerol backbone sn-1 ester-bond addition (acyl-type), an ether-bond (alkyl type) or a vinyl ether-bond is present (alkenyl-type) (Fig. 1). These phospholipid, lysophosphatidic acid is metabolized to a plurality of enzyme, via a plurality of specific receptors, cancer invasion, a fertilized egg landing, angiogenesis, involved in the formation of hair. Alkyl-lysophospholipids metabolites, platelet activating factor, via the receptor has the effect of bronchoconstriction. Alkenyl phospholipid is, also referred to as a plasmalogen, phospholipid in the living body 2 which occupies about the interrupt, especially cranial nerve, muscle, lymphocytes, macrophages and a high content of the. Biosynthesis of plasmalogen the failure, fatal neurological disease is known to exhibit a (non-patent document 1), its function will be often unknown.
In recent years, a phospholipid phospholipase A2 (PLA2) the decomposition enzyme is associated with various biological response has been reported (Non-Patent Document 2). PLA2 Is, phospholipid fatty acid degradation of enzyme lysophospholipid and generic groups, lipid mediators (local transiently acidic is, bioactivity of the bioactive lipid and are collectively referred to) starting the production of the enzyme and at the same time, the fatty acid metabolism and the regulation of energy balance, membrane enzyme involved in reconstruction. PLA2 In the genome of a mammal having a name corresponding to the 30 code and one or more molecules, these molecules can be controlled by a variety of biological response is apparent.
PLA2 Of 1 type (sPLA2-IIF) is PLA2G2F, certain lysophospholipid by production, epidermal thickening disease have been reported to be involved in the (non-patent document 3, Fig. 2). The mechanism is as follows. Is PLA2G2F, increases in psoriasis Th17 cytokines (IL-22) derived by the expression, secreted from the skin keratinocytes 1-(1Z-octadecenyl) -2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine( phosphatidylethanolamine-type plasmalogen, P-PE(18:0/22:6) ) to decompose, plasmalogen 1-O-1'-(Z) -octadecenyl-2-hydroxy-sn-glycero-3-phosphoethanolamine( LPEAT-type lysophosphatidyletanolamine, (18:0) P-LPE) is generated. P-LPE is generated, acting on the keratinocytes exacerbate inflammation and skin thickening by, epidermal thickening property involved in the disease progression.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOKUSHIMA UNIVERSITY
  • TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
  • 発明者(英語)
  • YAMAMOTO Kei
  • MURAKAMI MAKOTO
  • SAKASEGAWA Shinichi
国際特許分類(IPC)
ご興味のある方は、下記「問合せ先」へ電子メールまたはFAXでご連絡ください。

PAGE TOP

close
close
close
close
close
close